139 related articles for article (PubMed ID: 639696)
21. [Metastases of carcinoma of the breast to the choroid in the female (author's transl)].
Stolzenbach G; von Domarus D
Dtsch Med Wochenschr; 1978 May; 103(20):864-7. PubMed ID: 648368
[TBL] [Abstract][Full Text] [Related]
22. Rhythmic fluctuations of CEA serum levels in breast cancer patients.
Jäger W; Diedrich M; Sauerbrei W; Wildt L
Anticancer Res; 1987; 7(4B):711-5. PubMed ID: 3674759
[TBL] [Abstract][Full Text] [Related]
23. Differential immunocytochemical localization of tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) in breast cancer.
Björklund V; Björklund B
Cancer Detect Prev; 1983; 6(1-2):193-8. PubMed ID: 6883380
[TBL] [Abstract][Full Text] [Related]
24. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
[TBL] [Abstract][Full Text] [Related]
25. Demonstration of elevated anti-Lewis antibodies in sera of cancer patients using a carcinoembryonic antigen-polyethylene glycol immunoassay.
Pompecki R; Shively JE; Todd CW
Cancer Res; 1981 May; 41(5):1910-5. PubMed ID: 6163531
[TBL] [Abstract][Full Text] [Related]
26. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer.
Mughal AW; Hortobagyi GN; Fritsche HA; Buzdar AU; Yap HY; Blumenschein GR
JAMA; 1983 Apr; 249(14):1881-6. PubMed ID: 6834584
[TBL] [Abstract][Full Text] [Related]
27. [Relevance of CEA in benign breast disease (author's transl)].
Opri F; Kirchner H; Mayfeld K
Geburtshilfe Frauenheilkd; 1980 Jan; 40(1):51-4. PubMed ID: 7353775
[TBL] [Abstract][Full Text] [Related]
28. Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.
Paulick R; Caffier H; Paulick M
Cancer Detect Prev; 1987; 10(3-4):197-203. PubMed ID: 3568016
[TBL] [Abstract][Full Text] [Related]
29. Carcinoembryonic antigen: an invaluable marker for advanced breast cancer.
Pathak KA; Khanna R; Khanna HD; Khanna S; Gupta S; Khanna NN
J Postgrad Med; 1996; 42(3):68-71. PubMed ID: 9715319
[TBL] [Abstract][Full Text] [Related]
30. [The tumor markers TPA and CEA in the after care of breast cancer].
Beaufort F; Fueger GF; Steiner H
Wien Med Wochenschr; 1985 Feb; 135(4):85-8. PubMed ID: 2986366
[TBL] [Abstract][Full Text] [Related]
31. Lack of relationship between parity and level of carcinoembryonic antigen in women with breast cancer.
Heller R; Fisher R; Nash A; Knapp J
Anticancer Res; 1990; 10(6):1755-7. PubMed ID: 2285254
[TBL] [Abstract][Full Text] [Related]
32. [Diagnostic contribution of carcinoembryonic antigen (CEA) in the pleural fluid and serum of patients with metastatic pleural effusion caused by neoplasm of the breast].
Rapellino M; Obert R; Pecchio F; Casadio C; Oliaro A; Paisio B
Minerva Med; 1987 Jan; 78(2):103-5. PubMed ID: 3808402
[TBL] [Abstract][Full Text] [Related]
33. Carcinoembryonic antigen in patients with breast cancer: an adjunctive tool to monitor response and therapy.
Falkson HC; Van Der Watt JJ; Portugal MA; Pitout MJ; Falkson G
Cancer; 1978 Sep; 42(3):1308-13. PubMed ID: 698917
[TBL] [Abstract][Full Text] [Related]
34. [Clinical evaluation of the antioestrogenic agent tamoxifen in the treatment of metastatic breast cancer (author's transl)].
Szepesi T; Czech W
Wien Klin Wochenschr; 1978 Feb; 90(4):133-41. PubMed ID: 625990
[TBL] [Abstract][Full Text] [Related]
35. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K
Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913
[TBL] [Abstract][Full Text] [Related]
36. [Tissue polypeptide and carcinoembryonic antigens in patients with breast cancer].
Polevaia EB; Tkacheva GA; Ivanov VM; Koposova TL
Vopr Onkol; 1984; 30(3):9-13. PubMed ID: 6710954
[TBL] [Abstract][Full Text] [Related]
37. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
[TBL] [Abstract][Full Text] [Related]
38. Significance of carcinoembryonic and tissue polypeptide antigen determination in the diagnosis of metastases in breast cancer.
Kausitz J; Hupka S; Makaiová I; Michalíková B; Urbanová M; Bohunický L; Belovicová C
Neoplasma; 1986; 33(4):471-6. PubMed ID: 3762808
[TBL] [Abstract][Full Text] [Related]
39. [Rebound regression after additional hormonal treatment with ethinyl oestradiol of metastasising carcinoma of the breast in females: frequency and clinical significance (author's transl)].
Quednau D; Garbrecht M; Stolzenbach G; Nowakowski H
Dtsch Med Wochenschr; 1978 Dec; 103(51):2029-32. PubMed ID: 729476
[TBL] [Abstract][Full Text] [Related]
40. [Serial determination of carcinoembryonic antigen in the follow-up of patients with malignant tumours (author's transl)].
Eimermacher H; Schuster P; Beyer HK
Dtsch Med Wochenschr; 1981 Apr; 106(14):428-30. PubMed ID: 7215166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
